Deciphering the multifaceted significance of MPZL2 in pancreatic cancer via in-depth bioinformatics analysesCorrespondence

Pancreatic cancer, a deadly malignancy with a median survival of less than 1 year, urgently requires biomarkers for prognosis prediction. MPZL2, associated with poor outcomes in other cancers, was analyzed in pancreatic cancer using TCGA and GTEX data. Our study found increased MPZL2 expression in PAAD, which can distinguish patients from healthy individuals with an AUC of 0.919. High MPZL2 levels correlate with worse survival outcomes and identify malignant tumor cells as the primary source. CMap analysis suggests clofibrate may reverse MPZL2 - driven molecular changes. In conclusion, MPZL2 is a promising prognostic biomarker and therapeutic target in PAAD